$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

$elox Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000156459019041002 Filed on November 06, 2019

Income Statement

Concept	2019 Q3	2018 Q3	2018 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.980M	$5.950M	$9.560M
YoY Change	0.5%	1114.29%	2231.71%
% of Gross Profit
Research & Development	$6.801M	$5.415M	$4.150M
YoY Change	25.6%	65.09%	59.92%
% of Gross Profit
Depreciation & Amortization	$18.00K	$75.00K	$25.00K
YoY Change	-76.0%	581.82%	257.14%
% of Gross Profit
Operating Expenses	$12.78M	$11.36M	$13.54M
YoY Change	12.49%	184.0%	326.01%
Operating Profit	-$12.78M	-$11.36M	-$13.54M
YoY Change	12.49%	184.0%	326.01%
Interest Expense	-$100.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$96.00K	$199.0K	$137.0K
YoY Change	-148.24%	-597.5%	-119.6%
Pretax Income	-$12.88M	-$11.16M	-$13.41M
YoY Change	15.41%	780.84%	567.16%
Income Tax
% Of Pretax Income
Net Earnings	-$12.88M	-$11.16M	-$13.41M
YoY Change	15.36%	176.26%	245.69%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$322.5K	-$318.8K	-$421.2K
COMMON SHARES
Basic Shares Outstanding			33.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2018 Q3	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$64.94M	$55.34M	$63.41M
YoY Change	17.35%	5664.58%	211266.67%
Cash & Equivalents	$22.16M	$55.34M	$63.41M
Short-Term Investments	$42.78M
Other Short-Term Assets	$1.520M	$810.0K	$560.0K
YoY Change	87.65%	912.5%	124.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$403.0K
Total Short-Term Assets	$66.85M	$56.14M	$63.97M
YoY Change	19.08%	5297.88%	22746.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.090M	$345.0K	$302.0K
YoY Change	215.94%	762.5%	504.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$110.0K	$52.00K
YoY Change	111.54%	420.0%
Total Long-Term Assets	$1.210M	$397.0K	$302.0K
YoY Change	204.79%	-92.85%	-94.57%
TOTAL ASSETS
Total Short-Term Assets	$66.85M	$56.14M	$63.97M
Total Long-Term Assets	$1.210M	$397.0K	$302.0K
Total Assets	$68.06M	$56.54M	$64.27M
YoY Change	20.39%	757.89%	999.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.690M	$1.352M	$2.098M
YoY Change	25.0%	1129.09%	995.01%
Accrued Expenses	$5.610M	$3.727M	$2.258M
YoY Change	50.52%	1333.46%	583.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due	$3.490M
YoY Change
Total Short-Term Liabilities	$11.23M	$5.079M	$4.356M
YoY Change	121.11%	370.28%	57.26%
LONG-TERM LIABILITIES
Long-Term Debt	$11.19M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$410.0K
YoY Change
Total Long-Term Liabilities	$11.19M	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.23M	$5.079M	$4.356M
Total Long-Term Liabilities	$11.19M	$0.00	$0.00
Total Liabilities	$22.83M	$5.080M	$4.360M
YoY Change	349.41%	55.05%	-12.34%
SHAREHOLDERS EQUITY
Retained Earnings		-$72.12M	-$60.96M
YoY Change		-41.47%	-49.96%
Common Stock		$123.7M	$121.0M
YoY Change		23950.95%	41319.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$45.23M	$51.46M	$59.92M
YoY Change
Total Liabilities & Shareholders Equity	$68.06M	$56.54M	$64.27M
YoY Change	20.39%	757.76%	999.57%

Cashflow Statement

Concept	2019 Q3	2018 Q3	2018 Q2
OPERATING ACTIVITIES
Net Income	-$12.88M	-$11.16M	-$13.41M
YoY Change	15.36%	176.26%	245.69%
Depreciation, Depletion And Amortization	$18.00K	$75.00K	$25.00K
YoY Change	-76.0%	581.82%	257.14%
Cash From Operating Activities	-$11.32M	-$8.100M	-$8.510M
YoY Change	39.75%	1307.9%	1568.63%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$30.00K	-$40.00K
YoY Change	-33.33%
Acquisitions
YoY Change
Other Investing Activities	-$15.71M	-$10.00K
YoY Change	157000.0%
Cash From Investing Activities	-$15.73M	-$40.00K	-$40.00K
YoY Change	39225.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-120.0K	10.00K	53.67M
YoY Change	-1300.0%	-99.33%	17790.0%
NET CHANGE
Cash From Operating Activities	-11.32M	-8.100M	-8.510M
Cash From Investing Activities	-15.73M	-40.00K	-40.00K
Cash From Financing Activities	-120.0K	10.00K	53.67M
Net Change In Cash	-27.17M	-8.130M	45.12M
YoY Change	234.19%	-979.23%	-21585.71%
FREE CASH FLOW
Cash From Operating Activities	-$11.32M	-$8.100M	-$8.510M
Capital Expenditures	-$20.00K	-$30.00K	-$40.00K
Free Cash Flow	-$11.30M	-$8.070M	-$8.470M
YoY Change	40.02%		1560.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39067000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33451000
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-96000
	us-gaap	Net Income Loss NetIncomeLoss	-33158000
CY2019Q3	us-gaap	Depreciation Depreciation	18000
CY2019Q3	elox	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	2032000
CY2019Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1983000
CY2019Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	801000
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	233000
CY2019Q3	elox	Accrued Interest On Debt AccruedInterestOnDebt	96000
	us-gaap	Profit Loss ProfitLoss	-39241000
	us-gaap	Profit Loss ProfitLoss	-33158000
	us-gaap	Share Based Compensation ShareBasedCompensation	8631000
	us-gaap	Share Based Compensation ShareBasedCompensation	9608000
	us-gaap	Depreciation Depreciation	68000
	us-gaap	Depreciation Depreciation	121000
	elox	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	350000
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	378000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	940000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-178000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-856000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1730000
	elox	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-350000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30134000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22307000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	56041000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	13500000
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q3	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	403000
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	461000
CY2018Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	122000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7807000
CY2019Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11193000
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	409000
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	360000
CY2018Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1129000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	129825000
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	12000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86145000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	42911000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50718000
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35951537
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35860114
CY2018Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	91423
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13959000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18898000
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	199000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-174000
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.05
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39944324
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-12000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	228000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	401000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	41000
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40117186
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39977654
CY2019Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	139532
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6801000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5415000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20160000
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5978000
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5945000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18907000
	elox	Business Combination Acquisition Related Costs And Adjustment To Estimate On Accrued Expense BusinessCombinationAcquisitionRelatedCostsAndAdjustmentToEstimateOnAccruedExpense	594000
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	12779000
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	11360000
	us-gaap	Operating Expenses OperatingExpenses	39067000
	us-gaap	Operating Expenses OperatingExpenses	33451000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12779000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-11360000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	293000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-12875000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-11161000
	us-gaap	Net Income Loss NetIncomeLoss	-39241000
CY2019Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-12000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	12000
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12887000
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11161000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39229000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33158000
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35005979
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37394310
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31485067
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	150000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46281000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26456000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	48651000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24151000
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22195000
CY2019Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	40000
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-79000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40000
CY2018Q4	elox	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	864000
CY2018Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	555000
	elox	Increase Decrease In Advances From Collaboration Partners IncreaseDecreaseInAdvancesFromCollaborationPartners	403000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133000
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	22000
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	11000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42603000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-138000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	276000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1215000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	148000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	103000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53676000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31231000
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	55382000
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55336000
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	46000
CY2019Q3	elox	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations In Reconciliation CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsInReconciliation	22195000
CY2018Q3	elox	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations In Reconciliation CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsInReconciliation	55382000
	us-gaap	Interest Paid Net InterestPaidNet	703000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	79000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	104000
	elox	Noncash Acquisition Of Treasury Shares NoncashAcquisitionOfTreasuryShares	46000
	elox	Noncash Acquisition Of Treasury Shares NoncashAcquisitionOfTreasuryShares	83000
	elox	Non Cash Issuance Of Shares Upon Exercise Of Warrants NonCashIssuanceOfSharesUponExerciseOfWarrants	178000
	elox	Fair Value Of Warrants Issued In Connection With Long Term Debt FairValueOfWarrantsIssuedInConnectionWithLongTermDebt	421000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.09
	elox	Number Of Rare And Ultra Rare Disease Due To Premature Stoppage Of Codons NumberOfRareAndUltraRareDiseaseDueToPrematureStoppageOfCodons	1800
CY2019Q3	elox	Cash And Cash Equivalent And Available For Sale Debt Securities CashAndCashEquivalentAndAvailableForSaleDebtSecurities	64936000
CY2019Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2019Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	22155000
CY2019Q3	elox	Cash And Cash Equivalent And Available For Sale Debt Securities Amortized Cost CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCost	64924000
CY2019Q3	elox	Cash And Cash Equivalent And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	15000
CY2019Q3	elox	Cash And Cash Equivalent And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2019Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2019Q3	elox	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	667000
CY2019Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	533000
CY2019Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	403000
CY2019Q3	us-gaap	Prepaid Insurance PrepaidInsurance	269000
CY2018Q4	us-gaap	Prepaid Insurance PrepaidInsurance	251000
CY2019Q3	elox	Contract Receivable Current ContractReceivableCurrent	6000
CY2018Q4	elox	Contract Receivable Current ContractReceivableCurrent	20000
CY2019Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	492000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	452000
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	272000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5629162
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	204000
CY2018Q3	us-gaap	Depreciation Depreciation	75000
CY2018Q4	elox	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3086000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2562000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	985000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	305000
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	100000
	us-gaap	Operating Lease Cost OperatingLeaseCost	400000
	elox	Operating Lease Estimated Incremental Borrowings Rate OperatingLeaseEstimatedIncrementalBorrowingsRate	0.08
CY2019Q3	elox	Operating Lease Present Value At Inception OperatingLeasePresentValueAtInception	1500000
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	138000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	493000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	310000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	941000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	71000
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	870000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	541000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	490000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	310000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1341000
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4583000
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	5000000
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	5000000
CY2019Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	417000
CY2019Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15000000
CY2019Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1219000
CY2019Q3	us-gaap	Long Term Debt LongTermDebt	13781000
CY2019Q3	elox	Long Term Debt Maturities Final Fee Due LongTermDebtMaturitiesFinalFeeDue	-900000
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25000
CY2019Q1	elox	Restricted Stock Vested During Period Value RestrictedStockVestedDuringPeriodValue	-121000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	421000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2658000
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-11917000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	34433000
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	90000
CY2019Q2	elox	Restricted Stock Vested During Period Value RestrictedStockVestedDuringPeriodValue	-111000
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3016000
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	23000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-14449000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	55224000
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28000
CY2019Q3	elox	Restricted Stock Vested During Period Value RestrictedStockVestedDuringPeriodValue	-44000
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	50000
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2957000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	21361000
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	735000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-8591000
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	13505000
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	97000
CY2018Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	31000
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6178000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-13406000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	59916000
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2695000
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	51456000
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	40834
	elox	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	40834
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	400000
	elox	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	59707
	elox	Class Of Warrant Or Right Exercised In Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisedInPeriodWeightedAverageExercisePrice	3.01
CY2019Q3	elox	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	0
CY2019Q3	elox	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0
CY2019Q3	elox	Class Of Warrant Or Right Forfeited ClassOfWarrantOrRightForfeited	0
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	347241
	elox	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	59707
	elox	Class Of Warrant Or Right Forfeited ClassOfWarrantOrRightForfeited	4474
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	323894
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.77
	elox	Class Of Warrant Or Right Granted In Period Weighted Average Exercise Price ClassOfWarrantOrRightGrantedInPeriodWeightedAverageExercisePrice	11.02
	elox	Class Of Warrant Or Right Exercised In Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisedInPeriodWeightedAverageExercisePrice	3.01
	elox	Class Of Warrant Or Right Forfeited In Period Weighted Average Exercise Price ClassOfWarrantOrRightForfeitedInPeriodWeightedAverageExercisePrice	40.00
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.32
CY2018	elox	Class Of Warrant Or Right Expiration Period ClassOfWarrantOrRightExpirationPeriod	P3Y11M1D
	elox	Class Of Warrant Or Right Granted Expiration Period ClassOfWarrantOrRightGrantedExpirationPeriod	P10Y
	elox	Class Of Warrant Or Right Expiration Period ClassOfWarrantOrRightExpirationPeriod	P3Y11M26D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3261719
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1780200
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	91327
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	153552
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4797040
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1730606
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.43
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.98
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	12.76
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.96
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.69
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M21D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M14D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11650373
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1121950
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1024195
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2957000
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2695000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8631000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9608000
CY2019Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	272000
CY2018Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	223000
	us-gaap	Interest And Other Income InterestAndOtherIncome	766000
	us-gaap	Interest And Other Income InterestAndOtherIncome	368000
CY2019Q3	us-gaap	Investment Income Net InvestmentIncomeNet	92000
	us-gaap	Investment Income Net InvestmentIncomeNet	224000
CY2019Q3	us-gaap	Interest Expense Other InterestExpenseOther	460000
CY2018Q3	us-gaap	Interest Expense Other InterestExpenseOther	24000
	us-gaap	Interest Expense Other InterestExpenseOther	1164000
	us-gaap	Interest Expense Other InterestExpenseOther	75000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4726384

Files In Submission

Name	View Source	Status
0001564590-19-041002-index-headers.html	Edgar Link	pending
0001564590-19-041002-index.html	Edgar Link	pending
0001564590-19-041002.txt	Edgar Link	pending
0001564590-19-041002-xbrl.zip	Edgar Link	pending
elox-10q_20190930.htm	Edgar Link	pending
elox-20190930.xml	Edgar Link	completed
elox-20190930.xsd	Edgar Link	pending
elox-20190930_cal.xml	Edgar Link	unprocessable
elox-20190930_def.xml	Edgar Link	unprocessable
elox-20190930_lab.xml	Edgar Link	unprocessable
elox-20190930_pre.xml	Edgar Link	unprocessable
elox-ex101_267.htm	Edgar Link	pending
elox-ex311_9.htm	Edgar Link	pending
elox-ex312_7.htm	Edgar Link	pending
elox-ex321_8.htm	Edgar Link	pending
elox-ex322_6.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox

2019 Q3 Form 10-Q Financial Statement

#000156459019041002 Filed on November 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX Eloxx Pharmaceuticals, Inc. Stock $elox

2019 Q3 Form 10-Q Financial Statement

#000156459019041002 Filed on November 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELOX
Eloxx Pharmaceuticals, Inc. Stock $elox